# RetinalGenix Technologies

RetinalGenix Technologies is an Asset Manager.

## Overview

- **Organization type:** Asset Manager
- **Assets under management:** Undisclosed

## Regulatory record

- **Reports private funds:** No

## About

RetinalGenix Technologies is a medical technology firm focused on ophthalmic diagnostic devices. The company was formed to commercialize a platform that captures high-resolution retinal images without dilation, integrating artificial intelligence to detect pathologic biomarkers. This approach originated from the convergence of advanced optical engineering and machine learning, though specific founding names and dates are not available in the public record. Strategically, the company targets the intersection of ophthalmology, neurology, and chronic disease management. Its core product is a wide-field retinal camera designed for point-of-care use in primary care and specialist clinics. The system is being developed to screen simultaneously for diabetic retinopathy, age-related macular degeneration, glaucoma, and Alzheimer's disease risk through retinal vasculature and nerve fiber layer analysis. The business model anticipates revenue from device sales, per-scan fees, and potentially remote reading center services for clinical trial sponsors. Geographic focus for initial deployment is the United States. Operational scale remains opaque. The firm has not disclosed its funding history, total capital raised, or headcount. No recent regulatory approvals or commercial launches have been announced. Structurally, RetinalGenix differs from typical digital health plays in its focus on the diagnostic hardware-software combination rather than a software-only AI overlay on existing cameras. This integrated model, if successfully validated, could create switching costs and a proprietary data moat that pure-play AI diagnostics firms lack, though it also entails longer development cycles and higher regulatory burdens.

## Sectors

- Digital Health

## Questions

### What is RetinalGenix Technologies' core product?

The company is developing a wide-field retinal camera system that captures high-resolution images without requiring pupil dilation. The platform incorporates artificial intelligence to analyze retinal images for biomarkers linked to systemic and ocular diseases, including Alzheimer's disease, diabetic retinopathy, and glaucoma.

### Is RetinalGenix Technologies a publicly traded company?

Based on available public records, RetinalGenix Technologies does not appear to have completed an initial public offering on a major US exchange. The firm's capital structure, funding sources, and investor base have not been publicly disclosed.

### Has the firm received FDA clearance for its device?

There is no public record of RetinalGenix Technologies receiving 510(k) clearance, De Novo authorization, or pre-market approval from the U.S. Food and Drug Administration for its imaging platform or associated AI algorithms as of this profile's date.

## Related profiles

- [Newbridge Acquisition Ltd](https://altss.com/profile/newbridge-acquisition-ltd)
- [Leatt Corp](https://altss.com/profile/leatt-corp)

---

Last updated: 2026-08-11T02:43:31.692Z

Canonical page: https://altss.com/profile/retinalgenix-technologies-inc

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology